Summary
Over the last few years a lot of research has been done to develop novel metal-based anti-cancer drugs, with the aim of improving clinical effectiveness, reducing general toxicity, and broadening the spectrum of activity. The search for novel metal-based antitumour drugs other than Pt agents includes the investigation of the cytotoxic activity of copper(I/II) compounds. Among these copper agents, particular attention has been recently devoted to hydrophilic copper(I) species bearing phosphines because of their noteworthy stability in aqueous media together with their remarkable in vitro cytotoxic activity. In this study we report on the synthesis, characterization and cytotoxic assays of a series of Cu(I) complexes with tris(2-cyanoethyl)phosphine (PCN) and bis(2-cyanoethyl)phenylphosphine (PCNPh). They were prepared by reaction of [Cu(CH3CN)4]+ or CuX2 precursors with the pertinent phosphine in acetone or acetonitrile solutions producing compounds of the following formulation: [Cu(PCN)2]+ 2, [Cu(CH3CN)(PCN)]+ 3, [Cu(X)(PCN)] (X = Cl, 4; Br, 5), and [Cu(PCNPh)2]+ 6. The new copper(I) complexes were tested for their cytotoxic properties against a panel of several human tumour cell lines. Cellular copper uptake rate was correlated with cell growth inhibition in 2008 human ovarian cancer cells. Moreover, copper(I)-PCN complexes were evaluated for their ability to alter the most relevant mitochondrial pathophysiological parameters such as respiration, coupling, ATP-synthetase activity and membrane potential in isolated mitochondria. These data were correlated with changes in mitochondrial membrane potential and production of reactive oxygen species (ROS) in drug-treated 2008 cells.
Similar content being viewed by others
Abbreviations
- Cisplatin:
-
cis-diamminedichloroplatinum(II)
- MTT:
-
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- RF:
-
resistance factor
References
Marzano C, Pellei M, Tisato F, Santini C (2009) Copper complexes as anticancer agents. Anti-Cancer Agents Med Chem 9:185–211
Taylor MR, Gabe EJ, Glusker JP, Minkin JA, Patterson AL (1966) The crystal structures of compounds with antitumour activity. 2-keto-3-ethoxybutyraldehyde bis(thiosemicarbazone) and its cupric complex. J Am Chem Soc 88:1845–1846
Crim JA, Petering HG (1967) The antitumour activity of Cu(II)KTS, the copper (II) chelate of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone). Cancer Res 27:1278–1285
Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, Plezia P, Almassian B, Colacino E, Fischer J, MacDonald S (2002) Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 50:223–229
Murugkar A, Unnikrishnan B, Padhye S, Bhonde R, Teat S, Triantafillou E, Sinn E (1999) Hormone anchored metal complexes. 1. Synthesis, structure, spectroscopy and in vitro antitumour activity of testosterone acetate thiosemicarbazone and its metal complexes. Met-Based Drugs 6:177–182
Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, Faucette LF, Sung CM, Mong SM, Sadler PJ, Crooke ST (1986) In vivo antitumour activity and in vitro cytotoxic properties of bis[1, 2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res 46:5486–5493
Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 9:2467–2498
Ho YP, Au-Yeung SCF, To KKW (2003) Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Review 23:633–655
Zhang CX, Lippard SJ (2003) New metal complexes as potential therapeutics. Curr Opin Chem Biol 7:481–489
Snyder RM, Mirabelli CK, Johnson RK, Sung CM, Faucette LF, McCabe FL, Zimmerman JP, Whitman M, Hempel JC, Crooke ST (1986) Modulation of the antitumour and biochemical properties of bis(diphenylphosphine)ethane with metals. Cancer Res 46:5054–5060
Berners-Price SJ, Johnson RK, Mirabelli CK, Faucette LF, McCabe FL, Sadler PJ (1987) Copper(I) complexes with bidentate tertiary phosphine ligands: solution chemistry and antitumour activity. Inorg Chem 26:3383–3387
Berners-Price SJ, Sadler PJ (1988) Phosphines and metal phosphine complexes: relationship of chemistry to anticancer and other biological activity. Struct Bonding 70:27–10
Marzano C, Gandin V, Pellei M, Colavito D, Papini G, Gioia Lobbia G, Del Giudice E, Porchia M, Tisato F, Santini C (2008) In Vitro antitumour activity of the water soluble copper(I) complexes bearing the tris(hydroxymethyl) phosphine Ligand. J Med Chem 51:798–808
Porchia M, Benetollo F, Refosco F, Tisato F, Marzano C, Gandin V (2009) Synthesis and structural characterization of copper(I) complexes bearing N-methyl-1, 3, 5-triaza-7-phosphaadamantane (mPTA). Cytotoxic activity evaluation of a series of water soluble Cu(I) derivatives containing PTA, PTAH and mPTA ligands. J Inorg Biochem 103:1644–1651
Marzano C, Pellei M, Colavito D, Alidori S, Lobbia GG, Gandin V, Tisato F, Santini C (2006) Synthesis, characterization, and in vitro antitumour properties of tris(hydroxymethyl)phosphine Copper(I) complexes containing the new bis(1, 2, 4-triazol-1-yl)acetate Ligand. J Med Chem 49:7317–7324
Marzano C, Pellei M, Alidori S, Brossa A, Lobbia GG, Tisato F, Santini C (2006) New copper(I) phosphane complexes of dihydrobis(3-nitro-1, 2, 4-triazolyl)borate ligand showing cytotoxic activity. J Inorg Biochem 100:299–304
Rauhut M, Hechenbleikner I, Currier HA, Schaefer FC, Wystrach VP (1959) The cyanoethylation of phosphine and phenylphosphine. J Am Chem Soc 81:1103–1107
Vullo WJ (1966) Hydroxymethyl replacement reactions of tetrakis(hydroxymethyl) phosphonium chloride. Ind Eng Chem Prod Res Dev 5:346–349
Chylewski C, Jan G, Kurzen R, Meier M, Schellemberg M (1977) Chem Abs 2651:125–353
Streuli CA (1960) Determination of basicity of substituted phosphines by nonaqueous titrimetry. Anal Chem 32:985–987
Kosolapoff GM, Maier L (1972) In: Organic phosphorus compounds, Vol. 1. Wiley-Interscience, New York
Blake AJ, McQuillan GP (1984) Structures, vibrational spectra, and ligand behaviour of tris(2-cyanoethyl)phosphine and its oxide, sulphide, and selenide. J Chem Soc Dalton Trans 1849–1855
Mason MR, Verkade JG (1992) Fluoride-induced reduction of palladium(II) and platinum(II) phosphine complexes. Organometallics 11:2212–2220
Aquino MAS, Macartney DH (1987) Axial-ligand substitution reactions of dirhodium(II) tetraacetate with phosphines and phosphites in acetonitrile. Inorg Chem 26:2696–2699
Guy Orpen A, Pringle PG, Smith MB, Worboys K (1998) Synthesis and properties of new tris(cyanoethyl)phosphine complexes of platinum (0, II), palladium (0, II), iridium (I) and rhodium (I). Conformational analysis of tris(cyanoethyl)phosphine ligands. J Organomet Chem 550:255–266
Liu CW, Pan H, Fackler Jr GP, Wu G, Wasylishen RE, Shang M (1995) Studies of [Ag(PPh3)2]NO3, [Ag{P(CH2CH2CN)3}2]NO3 and [Ag{P(C6H4Me–m)3}2]NO3 by X-ray diffraction and solid-state nuclear magnetic resonance. J Chem Soc Dalton Trans 3691–3697
Khan NI, King C, Fackler GP Jr, Winpenny REP (1993) Syntheses and characterization of gold(I) and platinum(II) complexes containing tris(2-cyanoethyl)phosphine. X-ray crystal structures of [(CEP)2Au]Cl, cis-(CEP)(Et2S)PtCl2, and trans-(CEP)2PtCl2. Inorg Chem 32:2502–2505
Al-Fayez S, Abdel-Rahman LH, Shemsi AM, Seddigi ZS, Fettouhi M (2007) Synthesis and Crystal Structures of Bromo(1, 10-phenanthroline-N, N)tris(2-cyanoethyl)phosphinocopper(I) and Bromo(2, 2¢-bipyridine-N, N¢)tris(2-cyanoethyl)phosphinocopper(I). J Chem Crystallogr 37:517–521
Bowen RJ, Navarro M, Shearwood AM, Healy PC, Skelton BW, Filipovska A, Berners-Price SJ (2009) 1: 2 Adducts of copper(I) halides with 1, 2-bis(di-2-pyridylphosphino)ethane: solid state and solution structural studies and antitumour activity. Dalton Trans 28:10861–10870
Tisato F, Marzano C, Porchia M, Pellei M, Santini C (2010) Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev 30:708–749
McKeage MJ, Berners-Price SJ, Galettis P, Bowen RJ, Brouwer W, Ding L, Zhuang L, Baguley BC (2000) Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemoter Pharmacol 46:343–350
Braumann T (1986) Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships 373:191–225
Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumour cell lines using a microculture tetrazolium assay. Cancer Res 48:589–601
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Myers DK, Slater EC (1957) The enzymatic hydrolysis of adenosine triphosphate by rat liver mitochondria. I. Activities at different pH values. Biochem J 67:558–572
Estabrook RW (1967) Mitochondrial respiratory control and the polarographic measurement of ADP: O ratios. Methods Enzymol 10:41–47
Lehninger AL (1962) Water uptake and extrusion by mitochondria in relation to oxidative phosphorylation. Physiol Rev 42:467–517
Emaus RK, Grunwald R, Lemasters JL (1986) Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim Biophys Acta 850:436–448
Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42:872–881
Gandin V, Pellei M, et al. manuscript in preparation.
Bragadin M, Manente S, Marton D, Cima F, Rigobello MP, Bindoli A (2003) The interaction of zinc pyrithione with mitochondria from rat liver and a study of the mechanism of inhibition of ATP synthesis. Appl Organomet Chem 17:869–874
Sanghamitra NJ, Phatak P, Das S, Samuelson AG, Somasundaram K (2005) Mechanism of cytotoxicity of copper(I) complexes of 1, 2-bis(diphenylphosphino)ethane. J Med Chem 48:977–985
Zorov DB, Juhaszova M, Sollott SJ (2006) Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 1757:509–517
Radi R, Cassina A, Hodara R, Quijano C, Castro L (2002) Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 33:1451–1464
Acknowledgments
This work was financially supported by Ministero dell’Istruzione dell’Università e della Ricerca (PRIN 20078EWK9B). We are grateful to CIRCMSB (Consorzio Interuniversitario di Ricerca in Chimica dei Metalli nei Sistemi Biologici). The authors thank A. Moresco for elemental analyses and Dr. Bolzati for HPLC measurements.
Author information
Authors and Affiliations
Corresponding author
Additional information
Zanella and Gandin contributed equally to this work.
Rights and permissions
About this article
Cite this article
Zanella, A., Gandin, V., Porchia, M. et al. Cytotoxicity in human cancer cells and mitochondrial dysfunction induced by a series of new copper(I) complexes containing tris(2-cyanoethyl)phosphines. Invest New Drugs 29, 1213–1223 (2011). https://doi.org/10.1007/s10637-010-9466-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9466-7